DOSE RESPONSE STUDY OF BG9273(LFA 3 & IGG1 FUSION PROTEIN)

待验证的假设是LFA-III IgG1融合蛋白预防t细胞活化将对斑块型银屑病患者产生有益的治疗效果。克鲁格博士设计的一项多中心研究已经启动，计划在犹他中心招募10名患者。所有中心将招收200名患者，目标是让160名受试者完成至少8周的治疗。待测试的药物是一种二聚体蛋白，含有融合到人IgG1的铰链段和恒定区域的LFA-III的第一个细胞外结构域。LFA-III部分与t细胞上的CD2受体结合，IgG1部分与抗原呈递细胞上的Fc受体结合。该分子通过阻断皮肤抗原提呈细胞上表达的共刺激分子介导的增强的抗原提呈能力来阻断t细胞活化。初步证据表明，该制剂是安全的，但尚未对疗效数据进行分析。

The hypothesis to be tested is that prevention of T-cell activation by LFA-III IgG1 fusion protein will have a beneficial therapeutic effect in patients with plaque psoriasis. A multicenter study designed by Dr. Krueger has been mounted, with plans to enroll ten patients at the Utah Center. Two-hundred patients will be enrolled in all centers, with a goal of having 160 subjects complete at least eight weeks of therapy. The agent to be tested is a dimeric protein containing the first extracellular domain of LFA-III fused to the hinged segment and constant regions of human IgG1. The LFA-III portion binds the CD2 receptor on T-cells, and the IgG1 portion binds to the Fc receptor on antigen-presenting cells. The molecule was designed to block T-cell activation by blocking the enhanced antigen-presenting capacity mediated by the co-stimulatory molecules expressed on antigen-presenting cells of the skin. Preliminary evidence suggests that the agent is safe, but efficacy data have not yet been analyzed.